「智冉医疗」完成超3亿元A轮融资，加速侵入式脑机接口临床转化

Company Overview - Zhiruan Medical has completed over 300 million yuan in Series A financing, led by the Social Security Fund Zhongguancun Independent Innovation Special Fund, Junlian Capital, and IDG Capital, with continued investment from existing shareholders [1] - Since its establishment in 2022, the company has raised nearly 500 million yuan in total funding, which will primarily be used for the development of new technologies and large-scale clinical trials [1] Technology and Innovation - Zhiruan Medical focuses on invasive brain-computer interface (BCI) technology, which involves implanting electrodes directly into the brain to collect high-resolution neural signals and achieve precise neuron modulation [2] - The company has developed high-throughput flexible electrodes that have received patent authorization in both China and the United States, allowing for efficient neural signal collection and reduced immune response [2][3] - A fully implanted high-throughput wireless signal acquisition system has been created, capable of precise collection of neural action potentials from up to 1024 channels, with a significant reduction in power consumption [3] Research and Development - The company has established a high-precision brain data platform with over 20TB of animal neural data and 6TB of human deep brain data, which aids in training neural models and improving decoding performance [3] - Zhiruan Medical has developed a multi-degree-of-freedom implantation robot that allows for micron-level positioning accuracy, enhancing the efficiency and safety of electrode implantation [3] Industry Context - The global BCI industry is entering a rapid growth phase, with companies like Neuralink making progress in human clinical trials [4] - The shift from rigid to flexible electrodes is seen as crucial for improving signal quality and stability, as well as reducing immune response risks, which are key factors for clinical application [4] - Invasive BCI technology is expected to achieve breakthroughs in treating conditions such as spinal cord injuries, ALS, and depression [4]